Tag: Regenerative medicine
SCTbio Partners with Cyto-care to Enhance Cell Therapy Cryopreservation and Logistics Advancements in Europe
SCTbio, a comprehensive contract development and manufacturing organization (CDMO) with expertise in cell-based therapy and viral vectors, has entered into a collaboration agreement with Cyto-care.eu GmbH, a specialized firm in advanced solutions for cell therapy and regenerative medicine.
Together, they...
BioGrad to Open the UK’s Second Largest Biobank Facility in Liverpool
BioGrad is to open the UK's second largest biobank facility in Liverpool, as part of a £7.6m investment into a new headquarters at Wavertree Technology Park.
In collaboration with the University of Leicester, BioGrad biobank has already welcomed up to...
Stem Cell Banking: Current Trends, Benefits, Emerging Issues and Challenges
Recent scientific advancements have made stem cell therapy an emerging and promising area of research. The establishment of stem cell banks around the globe has been growing rapidly, aimed at preserving the characteristics of the cells, preventing contamination, and...
Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support Personalized Therapeutics Development
Generate Life Sciences (Generate) today announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, California which will enable end-to-end manufacturing for newborn stem cell biologics.
This facility will represent a big step in the evolution of Generate and...
The Gift Of Life Marrow Registry To Receive Advocacy Award At World Stem Cell...
The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in...
Mallinckrodt’s Cryopreserved StrataGraft Makes Phase III Progress Treating Thermal Burns
Mallinckrodt plc, a global biopharmaceutical company, has
announced positive top-line results from its pivotal Phase 3 clinical trial of
its investigational StrataGraft® regenerative tissue. The study, which met both
primary endpoints, evaluated the efficacy and safety of a single application of
StrataGraft in...
Biotime Has Licensed One Of Its Pluripotent Cell Lines To GoLiver
BioTime Inc. is a clinical-stage biotechnology company, headquartered in the San Francisco Bay Area, focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is...
AmnioFix® Injectable Granted RMAT Designation By The FDA For The Treatment Of Osteoarthritis Of...
MiMedx Group, Inc. developed the proprietary PURION® Process that separates placental tissues collected after birth, cleans and reassembles layers, and then dehydrates the tissue for long term storage under sterile conditions. The PURION® Process removes free blood while retaining...
Humacyte Funding Will Support Final Stage Clinical Development Of Its Regenerative Medicine
Humacyte, Inc., is a privately held clinical stage biotechnology company developing the technology of human acellular vessels (HAVs). It is a type of bioengineered vein. HAVs are produced in a cell culture bioreactor and then acellularized. Proposed uses include...
